Podiatry Management: an interview with Dr. Jeffrey Adler

08 April 2016 - Trade fairs & Congresses -

The special feature “Profiles in excellence 2016” in the Podiatry Management magazine, reports an interesting interview with Dr. Jeffrey Adler, DPM (Doctor of Podiatric Medicine) and Director of the Adler Footcare podiatric clinic of Greater New York. The doctor, who daily treats issues such as bursitis, plantar fasciitis and post-op problems, talks of MLS® Laser Therapy as the primary method for relieving this type of patients’ pain. His clinic has been equipped with the M6 laser device, supplied by Cutting Edge Laser Technology, the USA ASAlaser distributor, since 2013 and the podiatrist states that 95% of his patients treated with MLS® obtains an 80% pain reduction.
 

You might also be interested in ...

See all articles

Press - 29/11/2018
The press agency Italpress reports the success of the course sponsored by FIS - Federazione Italiana Scherma (Italian Fencing Federation), dedicated to traumatology in sports, with an extensive focus...
Press - 12/10/2018
The ASAlaser “highly technological” devices and the efficient therapeutic solutions are at home for the Taiwan national team (Chinese Taipei) at the Indonesia 2018 Asian Para Games. The...
Press - 08/10/2018
Doctor Alessandro Danieli, in charge of the Fisiodanieli centre, a specialist medical centre in Rome, has no doubts when interviewed by the capital’s magazine “In Roma”, controlled...
Formacion Laserterapia ASAlaser en LATAM
News - 18/03/2025
ASA continues its expansion in Latin America, strengthening the presence of MLS® Laser Therapy among doctors, physiotherapists and specialists in orthopaedics and rehabilitation. With a series of...
Press - 18/03/2025
Going beyond differences to promote a culture of respect and inclusiveness: with this objective, the Vicenza-based company is promoting a series of initiatives throughout 2025 aimed at raising...
M-Hi All Terrain
News - 12/03/2025
M-Hi All Terrain redefines the standards of MLS® Laser Therapy, combining portability, resistance and operational autonomy to offer effective treatments anywhere.